Trial Profile
Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-Morbid Conditions of Aspirin Exacerbated Respiratory Disease(AERD) and Allergic Asthma and Rhinitis.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Allergic rhinitis; Aspirin-induced asthma
- Focus Therapeutic Use
- 28 Feb 2017 New trial record